Drug Approval | February 24, 2024
Orchid Pharma's 'Exblifep' receives USFDA approval
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
Project achieves 30% reduction in hospital acquired infections and 24% reduction in the incidence of multi-drug resistant organisms
These digital avenues have not only revolutionized patient care but also opened up new opportunities for HCPs to build thought leadership in their respective fields
The Board has elected Dr. Ajit Shetty, who had served as the Company's Interim Chairperson of the Board since December 9, 2023, as Chairperson of the Board, effective February 13, 2024
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
The talk show will be held monthly via Medanta's YouTube, Facebook and LinkedIn channe
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
The company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies
The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
Subscribe To Our Newsletter & Stay Updated
